{"id":967375,"date":"2026-05-27T08:11:50","date_gmt":"2026-05-27T12:11:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"modified":"2026-05-27T08:11:50","modified_gmt":"2026-05-27T12:11:50","slug":"hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","title":{"rendered":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May  27, 2026  (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.<\/p>\n<p>\n        <strong>2026 Jefferies Global Healthcare Conference<\/strong><br \/>\n        <br \/>Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET<br \/>Location: New York, NY<\/p>\n<p>A live webcast of the fireside chat will be available for replay under \u201cEvents &amp; Presentations\u201d section in the Investors section of Hemab Therapeutics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W5VOKV6A71FbzJKgn9kdngO9bfVxJIKkQMUZcVcDhtzhBu5OiDr13M5Eneg2CqQfRNW1jfDDrMeYHT7sIOlwAg==\" rel=\"nofollow\" target=\"_blank\">hemab.com<\/a>.<\/p>\n<p>\n        <strong>About Hemab Therapeutics<\/strong>\n      <\/p>\n<p>Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab\u2019s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.<\/p>\n<p>Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W5VOKV6A71FbzJKgn9kdnjhs5wIjuRoOrFM1nJlrdXJZpoTplSkbsVH__mjEaryk1p1ABvy9ZpKxY3U1X4w1WQ==\" rel=\"nofollow\" target=\"_blank\">hemab.com<\/a>. Follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uwBzoRXstK3b6trDzv9ifg_6rhHlg8I5UW4labbP4kDR4a6Dp3Or5dLNZZHVh-K_jFk6x9mL18kZ1P_02VCGOQCuHQLhB1xbGhLPWwM2l9M=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wwKWXoo_m90Ja6lBjEBUBgvP-hJUiunHPMVtVPfEFg9E390xFWJl0IzqreK5RLYrSHGVefzQMslCQ4WhtjUepq36-itDfjHQCIB399Quy4Y=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MT3uOVetG_jAsSgNWoRdZFfgqaxQNue9K5WPfnP5_qBI9iPbIRDscpr097CRTSf5kPyshUYczLC7OYSMYra-bhj33FMlmh53ykaXKgpM9ZgYr1T1BIlD9yQMThXzuqtN\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5wf6PdI9qxk6YCf6BNYW1K8qz5uNeYhJJtjsoi_z_stvB-Jpr54LtFRWdD2IJ8pPM4c0iKiZ31b-u4SS1vdg7w==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Deerfield<br \/>Peg Rusconi <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QJdNVhIs-Y6N50SUnGXxkuwIlf61PFVbI4XJFstiZUa2wB4Cpp2rFzakDpSWbbDhI2BQ-EHNdxJVCS8TjxXDxvanPLABDJqNdni4kk-cn2hb4hM0agN6-7UawPJu0ih6\" rel=\"nofollow\" target=\"_blank\">peg.rusconi@deerfieldgroup.com<\/a><\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Hemab Therapeutics<br \/>Mads Behrndt<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TUtq2rPNPHiUXfflpe66Lcv7zR9t8CpE2uKYEmJqFW4zsyCaTJwYD7_5pKtZdpMUsGe60R1d4QsmllFR1Svy2YHnBQwP4OuahFuSQKTwE6w=\" rel=\"nofollow\" target=\"_blank\">investors@hemab.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjI0ZjA5ZjgtZmNiMC00ZTcyLWI2OGEtYTdhZDIxNDYzNzU1LTEzMjE4MjEtMjAyNi0wNS0yNy1lbg==\/tiny\/Hemab-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare Conference Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ETLocation: New York, NY A live webcast of the fireside chat will be available for replay under \u201cEvents &amp; Presentations\u201d section in the Investors section of Hemab Therapeutics\u2019 website at hemab.com. About Hemab Therapeutics Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967375","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare Conference Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ETLocation: New York, NY A live webcast of the fireside chat will be available for replay under \u201cEvents &amp; Presentations\u201d section in the Investors section of Hemab Therapeutics\u2019 website at hemab.com. About Hemab Therapeutics Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the &hellip; Continue reading &quot;Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T12:11:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\",\"datePublished\":\"2026-05-27T12:11:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"},\"wordCount\":241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\",\"name\":\"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\",\"datePublished\":\"2026-05-27T12:11:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare Conference Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ETLocation: New York, NY A live webcast of the fireside chat will be available for replay under \u201cEvents &amp; Presentations\u201d section in the Investors section of Hemab Therapeutics\u2019 website at hemab.com. About Hemab Therapeutics Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the &hellip; Continue reading \"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-27T12:11:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference","datePublished":"2026-05-27T12:11:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"wordCount":241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","name":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=","datePublished":"2026-05-27T12:11:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzI2MyM3NjIyNjgyIzIzMTAyNzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967375"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967375\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}